roverxena schreef op 24 maart 2014 11:53:
oppassen geblazen denk dat de rek eruit is bij pharming en grote burn out aanstaande
gewoon n tip du me niet afschieten maar doe er mee wat je wilt
Biotechnology stocks suffered their worst day since October 2011 on Friday, raising questions among investors whether the sector is finally running out of momentum.
The selloff started early, following news that U.S. lawmakers have asked Gilead Sciences Inc (GILD.O) to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs.
The Nasdaq biotechnology index .NBI fell 4.4 percent to 2,577.21, closing below its 50-day average for the first time since November 2013. In less than a month, the index posted daily declines of more than 2 percent four times.
"Once the Congress gets involved, there is a risk for the whole sector, especially if the focus of the action is primarily on pricing," said Tim Ghriskey, chief investment officer of Solaris